APPENDICES. A systematic review and economic model of the ...

Study Intervention Participants Outcomes
Core symptoms
Abbreviated Conners’ Rating Scale (ACRS);
parents, teachers, clinic
Reference
Buitelaar et al., 1996 44
Co-existent problems
Not reported
Educational performance
Not reported
Arm 1
Pindolol
During first 3 days, participants
received a single dose of 20 mg
(a.m.); thereafter they were treated
with two doses of 20 mg
administered at breakfast and noon
(Individual administering medication
not reported)
Source
CCOHTA Report
Setting
The Netherlands
Psychological function
Not reported
Inclusion criteria
1. Diagnosis according to DSM-III-R criteria
2. Scores in the clinical range on both CBCL and CTRS
hyperactivity factors
3. Deficits in attention performance on either a reaction-time
task or a continuous performance task in the
neuropsychological testing
4. No previous treatment with psychotropic medication
5. Clinical indication for drug treatment
6. No diagnosis or family history of tic disorder
7. No pervasive developmental disorder
8. No contraindications for treatment with beta-blockers
Design
Parallel trial
Depression or anxiety
Not reported
Diagnostic criteria
DSM-III-R
Number
Total randomised = 32 (male = 30)
Arm 1 = 11
Arm 2 = 10
Arm 3 = 11
Arm 2
MPH
During first 3 days, participants
received a single dose of 10 mg
(a.m.); thereafter they were treated
with two doses of 10 mg
administered at breakfast and noon
(Individual administering medication
not reported)
Duration
Referral period: August
1990–June 1993;
treatment period:
4 weeks
Quality of life
Not reported
Adverse events
Stimulant Drug Side Effects Rating Scale
(modified version): frequency and severity
(parents, psychiatrist)
Additional outcomes
Pulse
Blood pressure
Purpose
To compare the efficacy
and side-effects of
pindolol and MPH in
children with attentiondeficit/hyperactivity
disorder
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Total withdrawals = 0
Arm 3
Placebo
Administered twice daily (breakfast,
noon)
(Individual administering medication
not reported)
Health Technology Assessment 2006; Vol. 10: No. 23
Age
109.8 months (mean); 6–13 years (range); 20.2 months (SD)
IQ
93.2 (mean)
Co-morbid disorders
Conduct disorder: n = 20; depressive disorder: n = 8 (15%);
anxiety disorder: n = 22 (42%); epilepsy: n = 1
(NB: numbers for whole sample of 52)
Diagnostic subtypes
Not reported
Additional information
Previous medication:
Participants in the trial were required not to have previously
received psychotropic medication
225